Bafisontamab  (Synonyms: EMB-01)

Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity^[1].

[(G1 VK-CK-VH-CH1-h-CH2-CH3_L-kappa)_VH-CH1]-dimer

Humanized

Bafisontamab (EMB-01) induces significantly stronger anti-tumor activity in PDX and CDX tumor models than that of anti-EGFR mAb or anti-cMet mAb alone. Bafisontamab shows significant anti-tumor activity in anti-EGFR mAb resistant tumor model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

237.63 kDa

2437210-79-0

Liquid

Colorless to light yellow

[Bafisontamab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [(G1 VK-CK-VH-CH1-h-CH2-CH3_L-kappa)_VH-CH1]-dimer

• 
  Immobilized Bafisontamab can bind Human EGFR Protein (ECD, His Tag). The EC₅₀for this effect is 3.76 ng/mL.
• 
  Immobilized Bafisontamab can bind Human c-MET/HGFR Protein (ECD, His Tag). The EC₅₀ for this effect is 3.28 ng/mL.

• [1]. Ren F, et al. EMB-01: An innovative bispecific antibody targeting EGFR and cMet on tumor cells mediates a novel mechanism to improve anti-tumor efficacy. Cancer Research, 2020, 80(16_Supplement): 528-528.